Lykan Bioscience
Previously, Alan was a board member at 3i plc, led the build-out of the 3i Europe office network, and founded 3i’s healthcare sector team as Global Head of Healthcare. Subsequently, Alan was the founder, CEO, and Chairman of the Investment Committee at Hermes GPE, an active co-investor in private equity-backed healthcare.
Alan is currently a member of the board at RoslinCT, X-Chem, Ardena, Sterling, Linimed, and Alcaliber, and previously Quotient Sciences until its successful exit.
Alan holds a Bachelor’s degree in Law, and an MSc in Enterprise, and is a graduate of the Advanced Management Programme at INSEAD. Originally from Scotland, Alan has worked and lived across continental Europe as well as leading deals in North America. He was Chair of the BVCA and for a number of years chaired the BVCA Responsible Investment Advisory Board, and is currently Chairman of the European Healthcare Private Equity Association (eHCPEA).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lykan Bioscience
Lykan combines decades of industry experience with a drive to save lives. Lykan's goal is to provide the first true end-to-end solution in cell and gene manufacturing; ushering in a new era in the industry.